What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?
1
2 Answers
Mednet Member
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center
- Poorly controlled Hypertension
- Active flare of autoimmune disease
- On immunosuppressant therapies